LT3001 met primary safety endpoint. No symptomatic intracranial hemorrhage occurred. LT3001 showed pronounced neurological improvement in the majority of patients with baseline NIHSS ≥6 treated with LT3001. These data suggest that LT3001 has the potential to provide significant clinical benefit to patients up to 24 hours after the onset of […]